Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial
Annals of Rheumatic Diseases, 04/13/2012
Song IH et al. – Patients with axial spondyloarthritis treated with etanercept (ETA) over 1 year did not reach drug–free remission in a higher percentage compared to patients from a control group treated with sulfasalazine (SSZ).
At week 48, patients who reached study remission (Assessment of Spondyloarthritis international Society (ASAS) plus MRI remission) were followed up without active treatment up to 1 year.
In case of a flare, patients were treated with ETA for another year.
All patients who were not in ASAS plus MRI remission at week 48 were treated with ETA in year 2.
ASAS plus MRI remission at week 48 was reached significantly more often in ETA–treated compared to SSZ–treated patients (33% vs 11%, p=0.03).
However, the flare rate was not different between these two groups: 69% in the ETA group versus 75% in the SSZ group.
Only 8% of patients initially treated with ETA versus 3% of those initially treated with SSZ reached permanent drug–free remission (not significant).
After treatment with ETA over 1 year, patients with flare showed an improvement in all clinical and imaging variables.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.